title: Daylight PDT with MAL - current data and practical recommendations of an expert panel.
abstract: Photodynamic Therapy (PDT) is one of the standard treatment modalities for actinic keratoses (AKs). Daylight PDT (DL-PDT) with MAL cream is a rather recent development, which, instead of an artificial light source, uses daylight for the activation of the photosensitizer. The present review summarizes available data based on a selective literature search, highlights practical aspects, and reflects the authors' expert knowledge in using DL-PDT. With respect to efficacy, study data shows that DL-PDT is noninferior to conventional PDT (cPDT). However, given that DL-PDT is markedly less painful, it is significantly better tolerated than cPDT. In Europe, DL-PDT can be performed from March to October, on sunny as well as on cloudy days. UV protection of untreated areas of the body should be observed. Outside temperature should not fall below 10°C. On hot days, patients should be advised to stay in the shade if necessary. Representing a useful addition to current therapeutic options, DL-PDT with MAL cream is, among others, suitable for patients with field cancerization and/or those who have experienced severe pain associated with cPDT.
authors.affiliation: Skin Center Cologne, Cologne, Germany.
authors.forename: Wolfgang G
authors.initials: WG
authors.lastname: Philipp-Dormston
authors.affiliation: Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
authors.forename: Sigrid
authors.initials: S
authors.lastname: Karrer
authors.affiliation: Dermatology practice, Hildesheim, Germany.
authors.forename: Holger
authors.initials: H
authors.lastname: Petering
authors.affiliation: Skin Tumor Center of Charité, Berlin, Germany.
authors.forename: Claas
authors.initials: C
authors.lastname: Ulrich
authors.affiliation: Centroderm Hospital, Wuppertal and Witten-Herdecke University, Witten, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Dirschka
authors.affiliation: Department of Dermatology and Allergology, Munich University Hospital (LMU), Munich, Germany.
authors.forename: Carola
authors.initials: C
authors.lastname: Berking
authors.affiliation: Department of Dermatology, Ruprecht Karls University Heidelberg, Heidelberg, Germany.
authors.forename: Anke S
authors.initials: AS
authors.lastname: Lonsdorf
authors.affiliation: Department of Dermatology, University Hospital Düsseldorf, Düsseldorf, Germany.
authors.forename: Peter Arne
authors.initials: PA
authors.lastname: Gerber
authors.affiliation: Department of Dermatology and Dermato-oncology, Division of General Dermatology, Vienna, Austria.
authors.forename: Sonja
authors.initials: S
authors.lastname: Radakovic
authors.affiliation: Department of Dermatology, Inselspital Hospital, Bern University, Bern, Switzerland.
authors.forename: Robert E
authors.initials: RE
authors.lastname: Hunger
authors.affiliation: Department of Dermatology and Allergology, Vest Hospital, Teaching Hospital, Recklinghausen, Germany.
authors.forename: Rolf-Markus
authors.initials: RM
authors.lastname: Szeimies
mesh_terms: D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy* / Q000473:pathology; D008027:Light; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods* / Q000592:standards*; D017319:Photosensitizing Agents / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D017319:Photosensitizing Agents; C475457:methyl 5-aminolevulinate; D000622:Aminolevulinic Acid